# An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

> **NCT02678234** · PHASE3 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Infections, Respiratory Tract

## Interventions

- **DRUG:** Paracetamol, phenylephrine HCl, and vitamin C

## Key facts

- **NCT ID:** NCT02678234
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-02-01
- **Primary completion:** 2017-04-01
- **Final completion:** 2017-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.
- **Last updated:** 2018-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678234, "An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02678234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*